Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

NCT01907685 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Neoplastic Disease

Interventions

DRUG: AVE8062
DRUG: Docetaxel

Sponsor

Sanofi